Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer

被引：14
作者：
Motono, Nozomu [1 ]
Mizoguchi, Takaki [1 ]
Ishikawa, Masahito [1 ]
Iwai, Shun [1 ]
Iijima, Yoshihito [1 ]
Uramoto, Hidetaka [1 ]
机构：
[1] Kanazawa Med Univ, Dept Thorac Surg, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan
来源：
LUNG | 2023年 / 201卷 / 06期
关键词：
Cancer-inflammation prognostic index; Standardized uptake value; Non-small cell lung cancer; Prognosis; STAGE-I; ADJUVANT CHEMOTHERAPY; NUTRITIONAL INDEX; ADENOCARCINOMA; RECURRENCE; PREDICTOR; RESECTION; OUTCOMES; SUVMAX; RATIO;
D O I：
10.1007/s00408-023-00649-z
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Purpose Cancer-inflammation prognostic index (CIPI) is calculated by multiplying the concentration of carcinoembryonic antigen by neutrophil-to-lymphocyte ratio. CIPI has been reported as a prognostic factor for colorectal cancer. Although carcinoembryonic antigen and neutrophil-to-lymphocyte ratio have been reported as prognostic factors for non-small cell lung cancer (NSCLC), it has not been investigated whether CIPI is a useful marker.Methods We analyzed the prognostic factors, including CIPI, in 700 NSCLC patients treated by pulmonary resection. We also analyzed a subgroup of 482 patients with pathological stage I NSCLC.Result CIPI > 14.59 (P < 0.01), maximum standardized uptake value (SUVmax) > 5.35 (P < 0.01), lymphatic invasion (P = 0.01), and pathological stage (P < 0.01) were significant factors for relapse-free survival (RFS) in multivariate analysis. SUVmax > 5.35 (P < 0.01) and pathological stage (P < 0.01) were revealed as significant factors for overall survival in the multivariate analysis. In the subanalysis, CIPI > 14.88 (P = 0.01) and SUVmax > 5.07 (P < 0.01) were significant factors for RFS of pathological stage I NSCLC in multivariate analysis.Conclusion CIPI was a significant factor for RFS in NSCLC patients treated surgically, even in those with pathological stage I disease. SUVmax was also a significant factor for RFS and overall survival in NSCLC patients treated surgically, and for RFS in patients with pathological stage I NSCLC.
引用
收藏
页码：603 / 610
页数：8
相关论文
共 21 条
[1]  
BRINKMAN GL, 1963, AM REV RESPIR DIS, V87, P684
[2]   Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors [J].
Cvetkovic, Lena ;
Regis, Claudine ;
Richard, Corentin ;
Derosa, Lisa ;
Leblond, Antoine ;
Malo, Julie ;
Messaoudene, Meriem ;
Desilets, Antoine ;
Belkaid, Wiam ;
Elkrief, Arielle ;
Routy, Bertrand ;
Juneau, Daniel .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (05) :1550-1559
[3]   Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [J].
Felip, Enriqueta ;
Altorki, Nasser ;
Zhou, Caicun ;
Csoszi, Tibor ;
Vynnychenko, Ihor ;
Goloborodko, Oleksandr ;
Luft, Alexander ;
Akopov, Andrey ;
Martinez-Marti, Alex ;
Kenmotsu, Hirotsugu ;
Chen, Yuh-Min ;
Chella, Antonio ;
Sugawara, Shunichi ;
Voong, David ;
Wu, Fan ;
Yi, Jing ;
Deng, Yu ;
McCleland, Mark ;
Bennett, Elizabeth ;
Gitlitz, Barbara ;
Wakelee, Heather .
LANCET, 2021, 398 (10308) :1344-1357
[4]   Neutrophil: Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery [J].
Forget, Patrice ;
Machiels, Jean-Pascal ;
Coulie, Pierre G. ;
Berliere, Martine ;
Poncelet, Alain J. ;
Tombal, Bertrand ;
Stainier, Annabelle ;
Legrand, Catherine ;
Canon, Jean-Luc ;
Kremer, Yann ;
De Kock, Marc .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 :S650-S660
[5]   Carcinoembryonic antigen (CEA) as tumor marker in lung cancer [J].
Grunnet, M. ;
Sorensen, J. B. .
LUNG CANCER, 2012, 76 (02) :138-143
[6]   A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].
Kato, H ;
Ichinose, Y ;
Ohta, M ;
Hata, E ;
Tsubota, N ;
Tada, H ;
Watanabe, Y ;
Wada, H ;
Tsuboi, M ;
Hamajima, N ;
Ohta, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721
[7]   Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer [J].
Kim, Y. S. ;
Kim, S. J. ;
Kim, Y. K. ;
Kim, I. J. ;
Kim, Y. D. ;
Lee, M. K. .
NEOPLASMA, 2011, 58 (03) :245-250
[8]   Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis [J].
Li, Dan ;
Yuan, Xia ;
Liu, Jia ;
Li, Changling ;
Li, Weimin .
JOURNAL OF THORACIC DISEASE, 2018, 10 (09) :5298-5307
[9]  
Motono N., 2022, World J Surg Res, V5, P1401
[10]   Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma [J].
Motono, Nozomu ;
Ueno, Masakatsu ;
Tanaka, Makoto ;
Machida, Yuichiro ;
Usuda, Katsuo ;
Sakuma, Tsutomu ;
Sagawa, Motoyasu .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (23) :10171-10174
123